Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp (NASDAQ: DRIO) is a leader in digital therapeutics, revolutionizing chronic condition management through data-driven health solutions. This news hub provides investors and healthcare professionals with essential updates on corporate milestones, clinical validations, and strategic partnerships.
Access timely press releases covering earnings reports, product innovations, and business expansions. Our curated collection includes updates on Dario's integrated platform developments, partnership announcements with healthcare providers, and regulatory milestones in digital health.
Key focus areas include advancements in personalized coaching technologies, behavioral health integrations, and outcomes from clinical studies. Stay informed about DarioHealth's progress in merging life sciences with digital tools to improve chronic care management for employers, payers, and patients.
Bookmark this page for direct access to verified corporate communications. Check regularly for updates on DRIO's market-moving developments in the rapidly evolving digital therapeutics sector.
DarioHealth Corp. (NASDAQ-CM: DRIO) announced a contract with a large regional health plan to provide its digital therapeutic solution for diabetes to eligible Medicaid members in the mid-Atlantic region. Expected to contribute to revenue in Q2 2022, this partnership aims to improve access to innovative diabetes care and reduce medical costs for Medicaid participants, who face significantly higher healthcare expenses. DarioHealth’s digital therapeutics platform addresses various chronic conditions, emphasizing personalized experiences and behavior change for better health outcomes.
DarioHealth Corp. (Nasdaq: DRIO) is set to host an investor webinar on January 19, 2022, at 8 am ET, focusing on emerging digital health trends. The event will feature insights from industry experts Sari Kaganoff and David Kaplan, along with DarioHealth executives detailing the company's digital therapeutics platform and 2021 achievements. DarioHealth aims to transform healthcare with its AI-powered platform addressing chronic conditions like diabetes and hypertension. To register, visit their website.
DarioHealth Corp. (Nasdaq: DRIO) announced a strategic partnership with a leading employer benefits brokerage to provide its digital therapeutic solutions for diabetes, hypertension, and musculoskeletal health. This new employee health benefits product will be available to over 2,300 small business clients starting early 2022. DarioHealth was selected for its proven engagement and cost-effective clinical results, positioning it as the exclusive chronic condition management solution in the benefits package, potentially benefiting millions of small business employees.
DarioHealth Corp. (Nasdaq: DRIO) announced its Q3 2021 financial results, showcasing a remarkable 176% revenue growth year-over-year, reaching $5.6 million. Pro-forma gross margin improved to 45% from 26.9% a year prior. Despite robust revenue growth, the company reported an operating loss of $22.5 million, up 240.8% from Q3 2020. Dario secured 47 contracts to date, with a billion-dollar pipeline, primarily focused on multi-condition digital health solutions. The firm is well-funded with $51.3 million in cash, supporting its growth strategy in the competitive digital therapeutics market.
DarioHealth Corp. (Nasdaq: DRIO) has appointed Jerrod Helms as Chief Commercial Officer to enhance its growth in employer, payer, and provider markets amid significant commercial acceleration. Mr. Helms, with extensive sales leadership experience in healthcare, joins from Ginger and Headspace. The appointment aims to capitalize on rising demand for Dario's multi-chronic digital therapeutic solutions. The company is optimistic about expanding its market presence and achieving accelerated growth moving into 2022.
DarioHealth Corp. (NASDAQ: DRIO) is set to release its financial results for Q3 2021 on November 15, 2021, after trading. A conference call will occur on November 16, 2021, at 8:30 AM ET. Key executives including CEO Erez Raphael will lead the call.
Investors can dial in using the numbers 877-451-6152 (US) or 201-389-0879 (international). The webcast will be accessible [here](https://viavid.webcasts.com/starthere.jsp?ei=1511170&tp_key=13b2851117). Replays will be available until December 16, 2021.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
